Register for our free email digests:
Lanthio Pharma BV
Division of MorphoSys AG
Latest From Mindray Medical International Ltd.
Beijing-based vaccines group Sinovac Biotech is evaluating two privatization proposals after competing offers from its CEO and an EV17 vaccine rival have emerged in recent days.
Medical device companies working on the global stage are undergoing price and innovation productivity pressures just at the time that the markets are demanding a different type of service delivery from their suppliers. Smart manufacturers are reacting positively, with new commercial models, but they remain the exception to the rule, says the Boston Consulting Group, which is soon to release the second edition of its commercial benchmarking initiative.
Sinocare Group, a Chinese specialist in biosensor-based blood glucose monitoring devices, is expanding into the US market after agreeing to buy Nipro’s diabetes business, Nipro Diagnostics.
Two well recognized Chinese biopharma companies, BeiGene and Hutchison China MediTech, have recently filed for initial public offerings of American Depositary Shares on the US Nasdaq market, with the aim of becoming integrated companies able to tap global markets. Both see good reasons for pursuing a path different to other Chinese peers that have recently delisted in the US.
Drug Discovery Tools
- Molecular Diversity
- Large Molecule
- Drug Discovery Tools
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Renal System
- Western Europe
- Parent & Subsidiaries
- MorphoSys AG
- Senior Management
Heinz Schwer, PhD, MBA, CEO
Gert Moll, PhD, CSO
Sjoerd Wadman, VP, R&D
Michiel Lodder, PhD, VP, Bus. Dev.
- Contact Info
Lanthio Pharma BV
Phone: 50 30 50 240
P.O. Box 719 Groningen, 9700 AS
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.